Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate…

By L. Horn, D. Spigel, E. Vokes, E. Holgado, N. Ready, M. Steins, E. Poddubskaya, H. Borghaei, E. Felip, L. Paz-Ares and 19 more. Journal of Clinical Oncology, 2017

794 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/10a52bd53dc1f69a995beae35312e0b1c1428666

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. M. Hellmann
2. R. Edwards
3. Vincent A. Miller
4. Jing Wang
5. P. Jänne
6. J. Wolchok

In Pulmonary and Respiratory Medicine

1. P. Jänne
2. R. Edwards
3. Vincent A. Miller
4. William Pao

Citations in the corpus

• STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma (2018, methodology): “A fifth independent cohort of 44 patients with KRAS-mutant NSCLC (24 treated with nivolumab and 20 treated with docetaxel) with available STK11/LKB1 and TP53 mutational status and tumor cell PD-L1 expression from the CheckMate-057 (CM-057) international phase III randomized controlled trial (NCT0167”